Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TriSalus Life Sciences, Inc. filings document operating results, governance actions and capital-structure matters for an oncology-focused medical technology company. Form 8-K reports cover financial results, business updates, guidance, material events, leadership changes, board composition and Regulation FD disclosures tied to TriNav, PEDD and related oncology development activity.
Proxy materials describe shareholder voting matters, director elections, board committees, executive compensation and equity awards. The filing record also includes capital-structure disclosures for common stock and warrants, material-agreement categories, clinical or regulatory disclosure topics and risk-related information associated with commercializing PEDD infusion systems and developing investigational therapies for solid tumors.
TriSalus Life Sciences, Inc., an oncology-focused medical technology company, reported Q2 2026 revenue of $11,407 thousand, with cost of goods sold of $1,508 thousand and gross profit of $9,899 thousand. Operating expenses included research and development of $3,137 thousand, sales and marketing of $11,416 thousand, and general and administrative costs of $5,159 thousand. Loss from operations was $9,813 thousand, leading to a net loss of $9,187 thousand, or $0.16 per share, compared with a net loss attributable to common stockholders of $9,002 thousand, or $0.27 per share, in Q2 2025.
For the six months ended June 30, 2026, revenue was $20,306 thousand and net loss was $7,648 thousand, versus revenue of $20,380 thousand and net loss of $18,663 thousand in the prior-year period. Results reflected gains of $6,469 thousand from changes in fair value of SEPA, warrant and revenue base redemption liabilities and a $6,406 thousand gain from remeasurement of the contingent earnout liability.
Cash and cash equivalents increased to $46,288 thousand at June 30, 2026 from $20,439 thousand at December 31, 2025, mainly from $42,625 thousand of net proceeds from common stock issuances. Net cash used in operating activities was $16,609 thousand. Long-term debt under the OrbiMed Credit Agreement totaled $33,065 thousand, and total liabilities of $55,898 thousand were supported by stockholders’ equity of $6,550 thousand, compared with a stockholders’ deficit at year-end 2025.
TriSalus Life Sciences reported second quarter 2026 revenue of $11.4 million from TriNav system sales, up 1.7% year over year, with gross margin improving to 86.8% from 83.9% as unit costs declined. Operating loss widened to $9.8 million, and net loss attributable to common stockholders was $9.2 million, or $0.16 per share.
Non-GAAP adjusted EBITDA loss was $7.1 million, reflecting higher sales and marketing spending to expand the commercial organization, partly offset by lower research and development and general and administrative expenses. Cash and cash equivalents reached $46.3 million, supported by an equity offering, and total stockholders’ equity improved to $6.6 million from a deficit of $33.9 million at December 31, 2025.
The company maintained full-year 2026 revenue guidance of $54–$57 million, representing 19%–26% growth over 2025, and highlighted progress in its Pressure-Enabled Drug Delivery platform, including new real-world evidence in liver cancer, the PEDIR study submission, and ongoing Phase 1 trials of investigational immunotherapy nelitolimod.
TriSalus Life Sciences, Inc. filing amends a prior Schedule 13G to report that First Light Asset Management, LLC and Mathew P. Arens each may be deemed beneficial owners of 6,596,242 shares of common stock, representing 10.74% of the class. The filing is a joint statement and is signed on 07/07/2026.
TriSalus Life Sciences, Inc. Chief Financial Officer David Patience reported a routine tax-related share withholding. The company withheld 14,650 shares of common stock at $4.46 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Patience directly holds 261,107 shares of TriSalus common stock.
TriSalus Life Sciences CEO Mary T. Szela reported an acquisition of 3,990 shares of common stock. These shares were obtained at $3.87 per share through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this grant, she directly holds 1,077,683 TriSalus shares.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak acquired 561 shares of common stock at $3.8700 per share. The shares were obtained through the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Following this award, he directly holds 128,319 shares.
TriSalus Life Sciences, Inc. Chief Medical Officer Richard Henry received new equity compensation in the form of restricted stock units and stock options. He was granted 60,000 shares of common stock as restricted stock units, which will vest in four equal annual installments starting on June 29, 2027, assuming continued service. He also received an employee stock option for 120,000 shares of common stock at an exercise price of $4.74 per share, vesting over four years with one-fourth vesting on June 29, 2027 and the remainder monthly thereafter. Following these grants, he directly holds 90,000 shares of common stock and 253,000 stock options.
TriSalus Life Sciences, Inc. disclosed the initial equity holdings of its new Chief Medical Officer, Marshall Richard Henry, as he became an executive officer effective June 29, 2026. The filing shows direct ownership of 30,000 shares of common stock, acquired before his appointment.
Henry also holds several employee stock options giving rights to purchase additional common shares. These include options linked to 60,000, 48,000, and 25,000 underlying common shares at exercise prices of $5.55, $4.96, and $4.01 per share, expiring between 2034 and 2035. Footnotes describe time-based vesting schedules for both restricted stock units and these option grants, contingent on his continued service with the company.
TriSalus Life Sciences disclosed beneficial ownership for James J. Pallotta. The amendment to Schedule 13G/A shows Mr. Pallotta beneficially owns 3,188,711 shares, equal to 5.2% of common stock based on May 8, 2026, and that this total includes 114,268 shares underlying warrants exercisable into common stock. The filing lists the issuer address as 6272 W. 91st Ave., Westminster, CO 80031 and is signed by James J. Pallotta on May 20, 2026.
TriSalus Life Sciences, Inc. Chief Commercial Officer Richard Marshak reported a sale of 543 shares of common stock at $2.67 per share. According to the footnote, these shares were sold solely to satisfy tax withholding obligations from the vesting of previously granted restricted stock units and do not represent a discretionary sale. After this transaction, Marshak directly holds 125,101 shares of common stock.